AR046665A1 - Formulaciones orales de desoxipeganina y sus usos - Google Patents

Formulaciones orales de desoxipeganina y sus usos

Info

Publication number
AR046665A1
AR046665A1 ARP040104345A ARP040104345A AR046665A1 AR 046665 A1 AR046665 A1 AR 046665A1 AR P040104345 A ARP040104345 A AR P040104345A AR P040104345 A ARP040104345 A AR P040104345A AR 046665 A1 AR046665 A1 AR 046665A1
Authority
AR
Argentina
Prior art keywords
active
diseases
deficiency
administration
deoxipeganin
Prior art date
Application number
ARP040104345A
Other languages
English (en)
Inventor
Joachim Moormann
Klaus Opitz
Hans-Rainer Hoffmann
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of AR046665A1 publication Critical patent/AR046665A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Medicamentos en forma de película, de administración oral, que contienen el principio activo desoxipeganina y/o un derivado de la desoxipeganina y que pueden usarse para la administración a través de mucosas en particular, bucal, de estos principios activos. Reivindicación 16: Uso de al menos un principio activo colinérgico de acción central, seleccionado entre los principios activos nombrados en las reivindicaciones 1 y 2, para la preparación de un medicamento oral en forma de película para la administración del/de los principio(s) para el tratamiento de enfermedades o síntomas de enfermedades, que son originadas por una deficiencia de acetilcolina o en los que se presenta tal deficiencia, así como para el tratamiento de enfermedades en las que se presenta una deficiencia de aminas endógenas y/o que puedan ser influenciadas favorablemente por una inhibición de la monoamino-oxidasa.
ARP040104345A 2003-11-24 2004-11-24 Formulaciones orales de desoxipeganina y sus usos AR046665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10354894A DE10354894A1 (de) 2003-11-24 2003-11-24 Orale Formulierungen des Desoxypeganins und deren Anwendungen

Publications (1)

Publication Number Publication Date
AR046665A1 true AR046665A1 (es) 2005-12-14

Family

ID=34638177

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104345A AR046665A1 (es) 2003-11-24 2004-11-24 Formulaciones orales de desoxipeganina y sus usos

Country Status (20)

Country Link
US (1) US20070155774A1 (es)
EP (1) EP1827402A1 (es)
JP (1) JP2007512270A (es)
KR (1) KR20060123194A (es)
CN (1) CN1886137A (es)
AR (1) AR046665A1 (es)
AU (1) AU2004294690B2 (es)
BR (1) BRPI0416415A (es)
CA (1) CA2546950A1 (es)
DE (1) DE10354894A1 (es)
EA (1) EA008945B1 (es)
IL (1) IL175746A0 (es)
MX (1) MXPA06005733A (es)
MY (1) MY141008A (es)
NO (1) NO20062668L (es)
NZ (1) NZ547282A (es)
TW (1) TW200526223A (es)
UA (1) UA87291C2 (es)
WO (1) WO2005053698A1 (es)
ZA (1) ZA200603542B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2351315C2 (ru) * 2003-07-24 2009-04-10 Смитклайн Бичам Корпорейшн Пленки, растворяющиеся в полости рта
CN101384249B (zh) * 2006-02-17 2011-11-30 诺瓦提斯公司 可崩解口腔膜剂
DE102006027791A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag AchE-NMDA-Kombinationswafer
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
AU2011329066B2 (en) 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
WO2014018075A1 (en) 2012-07-23 2014-01-30 Crayola, Llc Dissolvable films and methods of using the same
DE102017127452A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Wasserlösliche Polymerklebschichten

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN142428B (es) * 1974-07-05 1977-07-09 Schering Ag
CH653550A5 (de) * 1981-10-20 1986-01-15 Sandoz Ag Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
JPS6393717A (ja) * 1986-10-09 1988-04-25 Sekisui Chem Co Ltd 口腔粘膜用粘着剤もしくは接着剤
CA2011423A1 (en) * 1989-03-07 1990-09-07 Peter M. Taylor Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
DE4018247A1 (de) * 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
US20020151467A1 (en) * 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
DE10119863A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10163667B4 (de) * 2001-12-21 2006-10-26 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen

Also Published As

Publication number Publication date
NZ547282A (en) 2009-10-30
WO2005053698A1 (de) 2005-06-16
ZA200603542B (en) 2007-02-28
CA2546950A1 (en) 2005-06-16
JP2007512270A (ja) 2007-05-17
DE10354894A1 (de) 2005-07-07
TW200526223A (en) 2005-08-16
CN1886137A (zh) 2006-12-27
EA200601015A1 (ru) 2006-10-27
IL175746A0 (en) 2008-04-13
MXPA06005733A (es) 2006-08-17
UA87291C2 (ru) 2009-07-10
BRPI0416415A (pt) 2007-05-08
EA008945B1 (ru) 2007-10-26
EP1827402A1 (de) 2007-09-05
US20070155774A1 (en) 2007-07-05
NO20062668L (no) 2006-06-09
MY141008A (en) 2010-02-12
KR20060123194A (ko) 2006-12-01
AU2004294690A1 (en) 2005-06-16
AU2004294690B2 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
UY28510A1 (es) Compuestos quimicos
AR037407A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CR8569A (es) Inhibidores de integrasa de vih
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
PE20020307A1 (es) Forma de dosificacion de farmaco activada por hidrogel
GT199900203A (es) Composiciones de celecoxib.
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AR068745A1 (es) Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
BR112016026667A8 (pt) comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
AR046665A1 (es) Formulaciones orales de desoxipeganina y sus usos
AR006345A1 (es) Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion.
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
AR033807A1 (es) Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y de sus sales aceptables para uso fisiologico, y las composiciones farmaceuticas que contiene estos compuestos
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.

Legal Events

Date Code Title Description
FB Suspension of granting procedure